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CD40L Blockade Prevents Autoimmune Diabetes
by Induction of Bitypic NK/DC Regulatory Cells
disruption of CD40:CD40L interactions necessary for
activation of antigen-presenting cells (APCs) bears
much promise and is currently undergoing preclinical
Dirk Homann,1,4 Angelika Jahreis,1,4
Tom Wolfe,1,2 Anna Hughes,1
Bryan Coon,1 Marianne J.B. van Stipdonk,2
and clinical evaluation (Kenyon et al., 1999; Kirk et al.,Kiley R. Prilliman,2 Stephen P. Schoenberger,2
1999; Davis et al., 2001).and Matthias G. von Herrath1,2,3
The potential for therapeutic costimulation blockade1Department of Neuropharmacology
has been evaluated in a variety of animal models forDivision of Virology
autoimmune disease. Lupus erythematosus was effec-The Scripps Research Institute
tively limited by B7 or CD40L blockade (Finck et al.,La Jolla, California 92037
1994; Mohan et al., 1995). Disruption of CD40:CD40L2 Division of Immune Regulation
interactions also suppressed collagen-induced arthritisLa Jolla Institute for Allergy and Immunology
(Durie et al., 1993), experimental autoimmune encephali-10355 Science Center Drive
tis (EAE; Gerritse et al., 1996; Howard et al., 1999), auto-San Diego, California 92121
immune thyroiditis (Carayanniotis et al., 1997), and my-
asthenia gravis (Im et al., 2001), but only combined B7/
CD40L blockade was effective in treatment of autoim-Summary
mune oophoritis (Griggs et al., 1996). In the nonobese
diabetic (NOD) mouse model for T1D, anti-B7.2 (aB7.2)Systemic treatment with antibody to CD40 ligand
therapy prevented and, in marked contrast, aB7.1 as(aCD40L) can prevent autoimmunity and transplant re-
well as combined aB7.1/B7.2 treatment enhanced onsetjection in several animal models and is currently under
of disease (Lenschow et al., 1995). A similar accelerationevaluation in clinical trials. While it is known that
of diabetes onset was observed in B7.1/B7.2-deficientaCD40L administration inhibits expansion and effector
mice and was attributed to defects in CD25CD4 regu-functions of aggressive T cells, it is still unclear
latory T cell homeostasis (Salomon et al., 2000). How-whether additional regulatory mechanisms are opera-
ever, even B7.2 blockade may not be beneficial undertive. Here we demonstrate that a single episode of
all circumstances as demonstrated by increased EAECD40L blockade during development of the autoag-
severity (Kuchroo et al., 1995) and reversal of protectiongressive immune response completely prevented au-
by pancreatic IL-4 expression when initiated during virustoimmune disease in the RIP-LCMV mouse model for
infection of NOD-IL-4 x RIP-LCMV mice (King et al.,virally induced type 1 diabetes. Interestingly, protec-
2001). CD40L blockade improved survival of functionaltion could be transferred by a highly potent, bitypic
islet isografts in NOD mice and DR-BB rats (Molano etcell population sharing phenotypic and functional
al., 2001; Kover et al., 2000) and, in combination withproperties of both natural killer (NK) and dendritic cells
a tolerance-based stem cell transplantation protocol,(DC). Furthermore, protection of prediabetic recipients
prevented rejection of islet allografts and diabetes inwas autoantigen specific and did not result in general-
NOD mice after as few as two antibody injections (Seungized immunosuppression. The origin, function, and
et al., 2000). Importantly, repeated aCD40L injectionstherapeutic potential of these bitypic NK/DC regula-
during early diabetes pathogenesis were effective intory cells is discussed.
preventing spontaneous disease onset in NOD mice.
Protection was associated with a decrease of autoag-Introduction
gressive effector T cells and interferon  (IFN) produc-
tion but not a switch from TH1- to TH2-type T cell re-Type 1 diabetes (T1D), a disease resulting from T cell-
sponses or induction of regulatory cells (Balasa et al.,
mediated autoimmune destruction of pancreatic  cells, 1997). Similar mechanisms have also been demon-
continues to pose an important health problem with no strated for CD40L blockade-mediated prevention of
available cure or prevention (Atkinson and Eisenbarth, EAE, thyroiditis, and myasthenia gravis (Howard et al.,
2001). Identification of individuals during the preclinical 1999; Carayanniotis et al., 1997; Im et al., 2001). How-
stage of disease offers a window for therapeutic inter- ever, additional effector mechanisms have been postu-
ventions that modulate activation, expansion, and/or lated to explain the marked and long-lasting reduction of
distribution of pathogenic T cells (Eisenbarth et al., aggressive CD4 and CD8 T cell activity and resulting
1998). Although transplantation of islets has recently therapeutic effects (Rossini et al., 1999; Graca et al.,
been much improved (Ramiya et al., 2000; Shapiro et 2000). The purpose of the present study was to evaluate
al., 2000), effective immunomodulatory approaches with the mechanism(s) by which costimulation blockade can
low systemic side effects remain an important goal for modulate autoimmunity and define paradigms for en-
maintaining both long-term graft acceptance and func- hancement of its protective capacity.
tion (Rossini et al., 1999). Among other strategies, block- As experimental system we chose the well-estab-
ade of costimulatory molecules B7.1 and B7.2 required lished RIP-LCMV model of T1D (Ohashi et al., 1991;
for activation of naive autoreactive lymphocytes and Oldstone et al., 1991; von Herrath et al., 1994). Here,
transgenic expression of proteins from lymphocytic
choriomeningitis virus (LCMV) is directed to pancreatic3 Correspondence: matthias@liai.org
4 These authors contributed equally to this work.  cells by use of the rat insulin promoter (RIP). While
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spontaneous diabetes is usually not observed in trans-
genic mice, disease can be initiated by LCMV infection
and occurs with rapid kinetics (day 14) in mice express-
ing the LCMV glycoprotein (RIP-GP mice) or delayed
kinetics (2–4 months) in RIP-NP mice expressing the
viral nucleoprotein (NP). The reason for the extended
prediabetic phase in the latter mice is concurrent NP
expression in the thymus and deletion of NP-specific
high-avidity cytotoxic T lymphocyte (CTL) precursors
(Oldstone et al., 1991; von Herrath et al., 1994). Virus-
specific CD8 T cells are the main initiators of the auto-
destructive process and both IFN and perforin are key
effector molecules in this model (von Herrath and Old-
stone, 1997; Seewaldt et al., 2000). While B cells and
antibody are not required for disease induction (Holz et
al., 2000), additional CD4 T cell help is necessary in
the RIP-NP but not -GP model (von Herrath et al., 1994).
Importantly, clinical disease occurs in both RIP-GP and
-NP mice only after the peak of the systemic antiviral
T cell response (day 8) and virus clearance (days 10–12).
We report here that a single episode of aCD40L block-
ade was effective in completely abrogating disease in
both rapid and slow onset RIP-LCMV diabetes models.
Protection, associated with a modest reduction of au-
toaggressive experienced/memory T cells but impaired
cytolytic activity, was mediated by a highly potent, bi-
typic natural killer/dendritic (NK/DC) regulatory cell pop-
Figure 1. Prevention of Type 1 Diabetes by Costimulation Blockade
ulation that prevented progression to clinically overt dia-
(A) Therapeutic efficacy of aCD40L and aB7 costimulation blockade.
betes in an antigen-specific manner. Incidence of diabetes is plotted as a function of the frequency of
antibody administration. While one or more injections of aCD40L
antibody (100 g) effectively prevented diabetes in LCMV-infectedResults
RIP-GP mice, five to seven treatments per week for a total of 2
weeks were required using aB7.1 and/or aB7.2 antibodies (100 g).Administration of a Single Dose of aCD40L Antibody
(B) Temporal susceptibility to therapeutic CD40L blockade. A single-
Completely Prevents Fast and Slow Onset Diabetes dose treatment (100 g) of aCD40L blocking antibody prevents vi-
Evaluation of different treatment regimens demon- rus-induced autoimmune diabetes when administered during a ther-
strated that a single administration of 100 g aCD40L apeutic window comprising days 3–10 after LCMV infection.
(C) Groups of RIP-GP and -NP mice were infected with LCMV andantibody was sufficient to prevent virus-induced diabe-
treated with different regimens of aCD40L, aB7.1, aB7.2, or controltes in RIP-LCMV mice (Figure 1A). Treatment was effec-
antibodies (100g/injection). Blood glucose values (BGV) were mon-tive for RIP-GP transgenic mice between days 3 and 10
itored twice weekly and onset of diabetes (defined as 2 consecutive
after infection and could be extended until day 21 for BGV of250 mg/dl) was recorded. Combined data was from two to
RIP-NP mice that develop diabetes with much slower three individual experiments per group. d, day; ND, not determined.
kinetics (2–4 months). CD40L blockade prior to virus
infection or outside the indicated time frames following
disease initiation had no significant therapeutic effect ulation of MHC class I or II occurred in treated mice,
leaving most islets virtually free of lymphocytes (Figure(Figures 1B and 1C and data not shown). These findings
indicate that CD40L blockade is highly effective when 2). In contrast to RIP-GP mice, B7 blockade did not
prevent slow onset diabetes in RIP-NP mice and evenadministered during a defined therapeutic window pre-
ceding clinical diabetes. demonstrated a detrimental acceleration of disease un-
der certain regimens (Figure 1C). Thus, administrationSince differential therapeutic effects of antibodies
blocking B7.1- versus B7.2-mediated interactions have of aCD40L antibody appears to be the more effective,
efficient, and safe treatment in the RIP-LCMV model.been described in the NOD mouse model for T1D, we
directly compared these treatments to the aCD40L ap-
proach in our model. Interestingly, neither a one-time Costimulation Blockade Impairs Neither Generation
of the Primary Antiviral Effector Responseinjection of aB7.1 or aB7.2 nor their coadministration
prevented diabetes in RIP-GP or -NP mice (Figure 1A nor Virus Clearance
In the RIP-LCMV model, antiviral T cell responses areand data not shown). Only repeated i.v. injections of
either antibody or both antibodies in combination over required for both diabetes initiation and virus clearance.
As expected from previous studies using CD40L- ora 2 week period achieved diabetes prevention in RIP-
GP mice. Under these conditions, treatment with aB7.2 CD28-deficient mice (Borrow et al., 1996; Bachmann et
al., 1998), aCD40L and aB7 treatment did not reduceantibody appeared slightly more effective than aB7.1
administration (Figures 1A and 1C). In parallel to these primary CTL activity or affect frequencies and functional
profiles of specific cytokine-producing CD8 T cellsfindings, infiltration of CD8 and CD4 (data not shown)
cells into islets was significantly reduced, and no upreg- (Figures 3A and 3B); virus clearance was achieved in all
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Figure 2. Reduction of T Cell Infiltration into Islets by Costimulation Blockade
Immunohistochemistry was performed on pancreatic sections prepared 14 days after LCMV infection and antibody treatment of RIP-GP mice.
Results for CD8 T cell stains are shown.
(A) No antibody treatment, diabetic.
(B) aB7.1 treatment daily d0-14 post-LCMV, not diabetic.
(C) aB7.2 treatment daily d0-14 post-LCMV, not diabetic.
(D) aCD40L treatment d4 post-LCMV, not diabetic.
groups without delay by days 10–12 postinfection (data effector function was demonstrable for costimulation-
blocked mice when in vitro restimulation cultures fornot shown). Interestingly, increased CTL activity ob-
served after aB7 treatment appeared primarily directed secondary CTL activity were conducted under subopti-
mal conditions (Figure 3F). Determination of specificagainst the dominant LCMV-NP epitope (data not
shown) and might thus contribute to the accelerated CTL precursor (pCTL) frequencies under standard con-
ditions, i.e., for 8–10 days in the presence of antigendisease kinetics in aB7-treated RIP-NP mice. Although
we observed a reduction of specific CD4 T cell frequen- and IL-2, allowed for expansion of functional CTLs in all
experimental groups. It is possible that this rescue ofcies in aCD40L-treated mice (Figure 3C), functional avid-
ities (Slifka and Whitton, 2001) of both specific CD8 secondary CTL activity is a consequence of partial an-
ergy induced by costimulation blockade (Schwartz,and CD4 T cells were identical among aCD40L- and
hamster Ig-treated control mice (Figure 3D). 1996). Interestingly, while pCTL frequencies were com-
parable among aB7-treated and untreated mice (data
not shown), aCD40L blockade resulted in reduced fre-
Costimulation Blockade Reduces Specific quencies concordant with the better therapeutic effi-
Experienced/Memory T Cells cacy of this treatment (Figure 3G).
In contrast to the primary CD8 CTL response, experi-
enced/memory CD8 T cell responses are significantly
reduced in the absence of CD40L (Borrow et al., 1998; Protection from Diabetes Induced by aCD40L
Blockade Can Be Transferred and Is SpecificWhitmire and Ahmed, 2000). Evaluation of systemic
(spleen) and local (pancreas draining lymph node) T cell The pronounced therapeutic efficiency of a single epi-
sode of CD40L blockade suggested the existence of anmemory using ex vivo MHC tetramer (data not shown)
and intracellular cytokine analysis indicated only a mod- active regulatory mechanism. To evaluate this possibil-
ity, we set up an adoptive transfer system as outlinederate reduction of LCMV-specific CD8and CD4T cells
in aCD40L- versus hamster Ig-treated control mice (Fig- in Figure 4A. Recipients were RIP-GP mice infected with
LCMV to initiate rapid onset diabetes. RIP-GP donorsure 3E). However, a qualitative impairment of cytolytic
Immunity
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Figure 3. Analysis of Primary and Secondary LCMV-Specific T Cell Responses in the Presence and Absence of Costimulation Blockade
(A) Eight days after infection with LCMV and treatment with aCD40L or hamster Ig (d3), primary CTL responses were evaluated on infected
(closed symbols) and uninfected (open symbols) target cells.
(B) Spleen cells obtained before (left panel), 8 days (middle panels), or 41 days (right panels) after LCMV infection and indicated antibody
treatment (day 3) were stimulated for 7 hr with GP33 and subsequently stained for CD8 and intracellular IFN and TNF. Dot blots are gated
on CD8 T cells.
(C) Frequencies of LCMV GP61- and NP309-specific CD4 T cells in spleen 8 days after infection as determined by intracellular cytokine staining
(black bars, aCD40L; gray bars, hamster Ig).
(D) Functional avidities of specific CD8 and CD4 T cells were determined by plotting the frequencies of detectable IFN-producing T cells
as a function of the peptide concentration used for 5 hr in vitro restimulation. Avidities for GP33-specific CD8 T cells were 1.98  0.17 
10	10 M for hamster Ig-treated (open circles) and 2.00  0.29  10	10 M for aCD40L-treated (closed circles) animals; avidities for GP61-specific
CD4 T cells were 7.57  2.81  10	8 M for hamster Ig- and 8.12  1.26  10	8 M for aCD40L-treated animals.
(E) Frequencies of epitope-specific memory T cells in spleen and pancreas draining lymph node (PDLN) evaluated 41 days after infection and
antibody treatment by intracellular cytokine staining (black bars, aCD40L; gray bars, hamster Ig).
(F) Secondary CTL activity determined 4 months after infection and restimulation culture under suboptimal conditions (see Experimental
Procedures) demonstrated impaired CTL expansion in all cultures from aCD40L- and aB7-treated mice. Specific killing at E:T ratio of 5:1 is
shown.
(G) Concomitant determination of pCTL frequencies under optimal culture conditions demonstrated reduced frequencies in aCD40L-treated
mice (black bars) as compared to control mice (gray bars) (left bars, p 
 0.0004). Similar differences were observed in mice 69 days after
treatment with adoptive transfer using cells from infected and aCD40L-treated (black bars) or hamster Ig-treated (gray bars) donors. All data
are from representative experiments involving at least three mice per group. Values represent mean 1 SE.
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Figure 4. Termination of Diabetes Progres-
sion by aCD40L-Conditioned Bitypic NK/DC
Regulatory Cells
(A) Experimental design: RIP-GP recipients
were infected with LCMV to initiate diabetes.
In parallel, RIP-GP donors were infected
(LCMV, VV, or mock infection) and subse-
quently treated with a single dose of aCD40L
or hamster Ig. Four to six days after infection,
single-cell suspensions were prepared from
donor spleens and transferred i.v. into predia-
betic recipients. In some experiments, donor
cells were depleted of or enriched for defined
cell subpopulations prior to adoptive transfer.
Diabetes onset in recipients was monitored
twice per week.
(B) Diabetes protection by costimulation
blockade can be transferred by immunother-
apy. Adoptive transfers of unfractioned
spleen cells from LCMV-infected/aCD40L-
treated donors prevented diabetes in 8/10 re-
cipients. In contrast, cells from donors that
received only aCD40L treatment or LCMV
challenge failed to protect prediabetic recipi-
ents. Similarly, cells from donors infected
with a heterologous virus (VV) and treated
with aCD40L had no therapeutic effect. n,
number of mice treated with 2–4  107 cells
per transfer.
(C) Protection is mediated by cells expressing
CD11c and NK1.1. In vitro depletion of indi-
cated cell populations from LCMV-infected/
aCD40L-treated donors demonstrated that
protection was conferred by DC (CD11c)
and/or NK cells (NK1.1) but not T or B lym-
phocytes.
(D) Transfer of 106 CD11c cells enriched
from spleens of LCMV-infected/aCD40L-
treated donors according to standard DC pu-
rification protocols prevented diabetes onset.
Direct ex vivo fractionating into DX5 and
DX5	 CD11c cells showed further that pro-
tection was mediated by NK/DC “hybrid”
cells coexpressing signature NK (DX5) and
DC (CD11c) markers (2  105 cells per
transfer).
were infected in parallel with LCMV or vaccinia virus LCMV-infected/aCD40L-treated donors protected 80%
of recipients from T1D (Figure 4B). It should be noted(VV) and treated 3 days later with a single injection of
aCD40L or control antibody. Four to six days after infec- that no surface-bound aCD40L or hamster Ig antibody
could be detected on transferred cell populations andtion, cells obtained from donor spleens were adoptively
transferred into prediabetic recipients. While all recipi- that protection could also be transferred using nontrans-
genic LCMV-infected/aCD40L-treated B6 donors (dataents developed diabetes in the absence of immunocy-
totherapy, transfer of unfractionated spleen cells from not shown). Control experiments demonstrated further-
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more that the protection was specific: neither cells from 30% of CD11c cells (Figure 5A). To minimize nonspe-
cific staining, Fc receptors were blocked on all cell prep-uninfected nor VV-infected and aCD40L-treated donors
could prevent diabetes. As expected, LCMV-infected arations, multiple stainings were performed using the
same antibodies conjugated to different fluorescentbut not aCD40L-treated donor cells also failed to dem-
onstrate a therapeutic effect (Figure 4B). All diabetic dyes, and NK and DC markers were analyzed using
nonadjacent fluorescence channels to minimize com-RIP-GP recipients developed disease within 2–3 weeks
following virus infection and no further incidences were pensation and autofluorescence artifacts during flow
cytometric cell acquisition. Upon virus infection, splenicrecorded at later time points. To evaluate specific T cell
responses by experienced/memory T cells, adoptive NK/DC cells expanded about 7-fold until day 5 (Figure
5B). During this activation phase, CD11c, DX5, andtransfers were also performed in B6 mice to avoid con-
founding effects due to diabetes development. Sixty- NK1.1 expression was concomitantly upregulated (Fig-
ures 5C and 5D). Further phenotypic analysis of threenine days after transfer, recipients of LCMV-infected/
aCD40L-treated donor cells retained virus-specific distinct cell populations (CD11c/DX5, CD11c/DX5	,
and CD11c	/DX5) at the height of expansion demon-IFN CD8 and CD4 T cells at frequencies compara-
ble to recipients of LCMV-infected/hamster Ig-treated strated bitypic CD11c/DX5 cells to be a heterogenous
cell population with additional features of DC and NKcontrol cells. However, pCTL in the former group were
8-fold lower than in the latter group (Figure 3G). These cells. In particular, B7.1, the more APC-restricted of the
B7 markers, was detected at levels comparable to “nor-findings provide strong evidence for a regulatory cell
population that is generated only in the specific context mal” CD11c/DX5	 DCs, while MHC II levels, detected
with two different IAb-specific monoclonal antibodies,of early diabetogenic (LCMV-specific) but not heterolo-
gous (VV-specific) immune responses and aCD40L were reduced as compared to DX5	DCs. Only a fraction
of the bitypic NK/DC cells expressed CD8 or CD4 core-blockade.
ceptors or TCR, ruling out a role for NK T cells (Figure
6A). This observation was confirmed by failure ofProtection Is Conferred by a Bitypic CD11c/DX5
CD11c/DX5 cells to bind CD1d tetramers (data notRegulatory Cell Population
shown). As observed for protection after adoptive trans-To further delineate the putative regulatory cell popula-
fer, phenotypic analyses of RIP-GP and nontransgeniction, we carried out a series of depletion and enrichment
B6 mice gave equivalent results.studies using LCMV-infected/aCD40L-treated donors
Finally, we evaluated the capacity of bitypic NK/DC(Figures 4C and 4D). Unexpectedly, depletion of CD4
cells to perform NK- or APC-like functions. CD11c/or CD8 T as well as B cells did not abrogate the thera-
DX5 but not CD11c/DX5	 cells purified ex vivo frompeutic effect of the transferred cell populations. In con-
LCMV-infected mice demonstrated high killing of NK-trast, depletion of cells bearing signature markers for
sensitive RMAS and YAC target cells. Furthermore, andeither DCs (CD11c) or NK cells (NK1.1) was associated
in agreement with the recent identification of CD8	/with a complete loss of diabetes protection (Figure 4C).
CD4	 DC as the main IFN producers among DCsAlthough CD11c and NK1.1 depletions were not com-
(Hochrein et al., 2001), IFN production was preferen-plete, reductions of 70%–80% were sufficient to abro-
tially localized to the predominantly CD8- and CD4-neg-gate the transfer of protection, indicating a quantitative
ative NK/DC cells (Figure 6B). To assess the potentialthreshold. To verify a therapeutic role for dendritic cells
for processing and presentation of unrelated antigens,in these experiments, we enriched DCs by two different
purified DC and NK/DC cells were incubated with oval-methods as outlined in Experimental Procedures (Ruedl
bumin (OVA), followed by coculture with an OVA257-spe-et al., 1996; Ridge et al., 1998). As shown in Figure 4D,
cific T cell hybridoma (B3Z) and subsequent determina-transfer of 106 enriched CD11c DC but not ex vivo
tion of B3Z activation in a chromogenic assay (Figurepurified CD4 T cells prevented development of diabe-
6C). Although not quite as efficient as DX5	 DCs, NK/tes in the recipients. Since we had noticed in concurrent
DC cells clearly demonstrated proficient OVA pro-analyses that virus infection expands a population of
cessing and presentation which, in conjunction with theCD11c cells that coexpresses NK1.1 and the pan-NK
expression of costimulatory molecules, is compatiblemarker DX5 (Figure 5), we further fractionated CD11c
with a more generalized APC function.cells directly ex vivo into DX5 and DX5	 cells. Indeed,
adoptive transfer of DX5 but not DX5	 CD11c cells
mediated diabetes protection (Figure 4D). In contrast Discussion
to mice protected by antibody treatment, diabetes-free
recipients of adoptive transfers, especially those that We have initiated the present study to evaluate the
experienced transient elevations of blood glucose, ex- mechanistic basis for therapeutic costimulation block-
hibited mild infiltration of islets by CD8 and CD4 ade and have identified a cell population with regulatory
T cells. We have thus identified a highly potent popula- function that shares features of both natural killer and
tion of regulatory cells that shares phenotypic properties dendritic cells. Our results demonstrate that bitypic NK/
of both DC and NK cells. DCs generated in the context of a developing autoim-
mune response and concurrent CD40L blockade can
prevent autoimmune disease in a specific manner afterKinetic, Phenotypic, and Functional Characterization
of Bitypic NK/DC Cells adoptive transfer into prediabetic recipients.
While costimulatory molecules are critical for genera-The presence of DX5/CD11c cells was not limited to
spleens of virus-infected animals. Splenocytes obtained tion of immune responses against purified proteins or
peptides, cellular immunity to a variety of pathogens,from uninfected animals showed DX5 coexpression on
Bitypic NK/DC Cells Prevent Type 1 Diabetes
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Figure 5. Kinetics of NK/DC Expansion and Activation
(A) Spleen cells of uninfected (d0) and LCMV-infected (d5) B6 mice were stained for CD11c, DX5, and NK1.1. Values in histograms indicate
percentage of NK1.1 cells among indicated CD11c/DX5 subsets.
(B) Expansion and contraction of NK/DC populations in spleen following LCMV infection.
(C and D) NK/DC cells (CD11c/DX5) increase CD11c and DX5 expression, while CD11c/DX5	 dendritic cells downregulate CD11c and
CD11c	/DX5 NK cells maintain unchanged levels of DX5 expression. The geometric mean of fluorescence intensity (GMFI) of indicated
subsets is depicted as a function of time after infection.
including LCMV, can be induced in the absence of such prevention was only effective when aCD40L treatment
was initiated during the systemic T cell expansion phasemolecules (Bachmann et al., 1998). How then can the
effectiveness of therapeutic costimulation blockade and (fast onset RIP-GP model) or expansion/contraction
phase (slow onset RIP-NP model), i.e., during the timeapparent costimulatory independence of the virus-spe-
cific/diabetogenic T cell response be reconciled? In the frame in which the quality of virus-specific T cell re-
sponses (but not effective virus control) is shaped byabsence of CD40L, generation of primary LCMV-specific
CD8 CTL and virus control is unaffected (Borrow et CD40:CD40L interactions.
While the details of the protective mechanism remainal., 1996). However, further analysis of specific T cell
immunity in CD40L-deficient mice revealed an impaired to be elucidated, the efficiency of aCD40L blockade
is remarkable given that the powerful systemic LCMVinduction of primary CD4 T cell effectors, an exagger-
ated contraction phase leading to reduced but stable response and rapid diabetes onset in RIP-GP mice make
this model particularly refractory to therapeutic immunelevels of experienced/memory CD8 T cells as well as
compromised protective immunity (Borrow et al., 1998; modulation. Since CD40L-mediated signals directly ac-
tivate DCs (Bennett et al., 1998; Ridge et al., 1998;Whitmire et al., 1999; Whitmire and Ahmed, 2000).
In agreement with these observations, temporary dis- Schoenberger et al., 1998), we speculated that altered
DC function during CD40L blockade might contribute toruption of CD40:CD40L interaction by antibody block-
ade did not alter primary CTL activity in RIP-LCMV mice. the prevention of autoimmune disease. Indeed, adoptive
transfer of CD11c cells enriched from LCMV-infected/Pancreatic cytokine analysis by ribonuclease protection
assay confirmed that protection was not associated with aCD40L-treated donors prevented progression to clini-
cally overt diabetes in recipients.a “TH1- to TH2-switch” but rather locally reduced IFN
and TNF production (data not shown) as reported pre- DCs are highly potent immunostimulatory cells en-
gaged in facilitated antigen transport to lymphoid tis-viously for NOD mice protected by CD40L blockade
(Balasa et al., 1997). While levels of experienced/mem- sues and efficient priming of T cell responses (Bancher-
eau and Steinman, 1998). While immunization with DCsory T cells were modestly reduced (2-fold at most using
MHC tetramers) in aCD40L- as compared to hamster constitutively expressing viral epitopes gave rise to dia-
betes in the RIP-GP model, adoptive transfer of pep-Ig-treated mice, qualitative differences came to the fore
under the assay conditions employed for pCTL analysis tide-coated DCs was relatively inefficient due to rapid
turnover of exogenously loaded peptides and resultingand indicated about 8-fold reduced frequencies in
aCD40L-treated mice. It should be noted that diabetes limitations in the differentiation of effector CD8 T cells
Immunity
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(Ludewig et al., 2001). Moreover, induction of disease,
CD4-independent after LCMV infection, now required
specific CD4 help (or in vivo CD40 crosslinking) (Lude-
wig et al., 2001). The requirements for DC-mediated
modulation of ongoing immune responses rather than
initiation of de novo immunity appear to be less strin-
gent. Transfer of peptide-coated DCs into LCMV-
infected NOD-IL-4 x RIP-NP F1 crosses reversed the
protective effect afforded by pancreatic IL-4 expression
in this model (King et al., 2001). Interestingly, the same
preparation of DCs prevented diabetes after transfer
into LCMV-infected IL-4-negative F1 crosses that are
otherwise susceptible to rapid disease onset (King et
al., 2001). The latter finding is similar to our observation
of CD11c cell-mediated protection but differs in that
costimulatory blockade was not required for the thera-
peutic effect. In our experiments, transfer of CD11c
cells from LCMV-infected mice in the absence of costi-
mulation blockade did not prevent diabetes (data not
shown). The reason for this discrepancy may be related
to different genetic backgrounds but remains unclear.
Further experiments indicated that only aCD40L-
treated donors infected with LCMV but not a heterolo-
gous virus generated protective regulatory cells. The
observed antigen specificity is likely a consequence of
treatment initiation during a defined therapeutic window
when costimulation blockade may result in conditioning
of CD11c cells that preferentially present LCMV epi-
topes and thus modulate the developing LCMV-specific
T cell response. The virtual absence of T cell infiltration
in many islets of mice protected by antibody treatment
suggests furthermore that local (pancreatic) modulation
of T cell immunity is particularly susceptible to CD40L
blockade. It is also in apparent contrast to the benign
islet infiltration inevitably associated with other immuno-
modulatory interventions. Here, protection relied on ini-
tial islet destruction, antigen release, and local presenta-
tion and activation of (insulin-specific) regulatory T cells
Figure 6. Phenotypic and Functional Properties of NK/DC Regula- in the draining lymph node that in turn modulated APC
tory Cells function to locally suppress LCMV-specific/diabeto-
(A) Phenotypic analysis of DC and NK cells. Spleen cells from LCMV- genic T cell responses (Homann et al., 1999). The regula-
infected and aCD40L-treated RIP-GP mice were analyzed for ex- tory CD11c cells identified in the current study can
pression of CD11c, DX5, and indicated additional surface markers.
presumably directly engage LCMV-specific T cell immu-Marker expression on live cells in three distinct subsets (CD11c/
nity and thus avoid even mild islet destruction underDX5, black bars; CD11c/DX5	, gray bars; CD11c	/DX5, white
appropriate therapeutic conditions. While diabetogenicbars) is displayed. Similar results were obtained using hamster Ig-
treated RIP-GP mice or B6 mice (data not shown). T cells are of defined specificity in our model system,
(B) Differential effector functions of DC-NK subsets. DX5 and DX5	 it should be noted that any concurrent effector T cell
CD11c cells were purified 5 days after LCMV infection and tested activity mounted during costimulation blockade (such
for ex vivo NK activity. Killing of uninfected RMAS and YAC cells as accompanying  cell-specific T cell responses of
by DX5 (black bars) and DX5	 (gray bars) CD11c cells at an E:T
differential specificity) should also be affected. Specificratio of 100:1 is shown. Cytokine production by indicated DC-NK
suppression of autoimmune responses can thus besubsets among unfractioned splenocytes was determined after 5
achieved without complete knowledge of the self-anti-hr in vitro activation (CD11c/DX5, black bars; CD11c/DX5	, gray
bars; CD11c	/DX5, white bars). gens involved. Furthermore, due to the temporal con-
(C) APC function of DC and NK/DC cells. Purified DX5 and DX5	 straints of therapeutic intervention (single antibody
CD11c cells (d5 after LCMV) were cultured overnight in the pres- injection or transfer of CD11c cells with very short half-
ence or absence of ovalbumin (OVA), and the capacity for antigen life [Kamath et al., 2000]), protected mice exhibited un-
processing and presentation was subsequently determined by co-
impaired immunity to unrelated pathogens (data notculture with the KbOVA257-specific B3Z T cell hybridoma transfected
shown).with a NFAT-lacZ reporter construct. Negative and positive controls
In attempting to correlate the protective function ofwere OVA-loaded EL4 thymoma cells and OVA257 peptide-pulsed
EL4 cells, respectively. Values represent SEM of stimulator:B3Z co- CD11c cells conditioned by LCMV infection and dis-
cultures at 1:2 ratios assayed in triplicate. Compared to OVA-loaded rupted CD40:CD40L interactions with phenotypic
EL4 stimulators (negative control), B3Z responses were significantly changes on those cells, we noted an upregulation of
higher in the presence of OVA and DX5	 (p  0.0001) or DX5 (p 
 the NK markers DX5 and NK1.1. Subsequent adoptive
0.0002) stimulators.
transfer studies showed that the protective function of
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appropriately conditioned CD11c cells resided in the sponses (Horwitz et al., 1997; Kos, 1998). While we have
DX5 fraction. What is the origin of these NK/DC hybrid ruled out a simple fusion of interacting DC and NK cells
cells? There are several, not mutually exclusive possibili- by measuring DNA content in NK/DC cells (data not
ties. Similar to subpopulations of T cells which upon shown), the potential for target cell molecule acquisition
activation express APC (CD11b, CD11c) and NK (NK1.1, has been described for activated T and B cells and
DX5) markers (McFarland et al., 1992; Huleatt and Le- recently also for DCs (Harshyne et al., 2001). It is thus
Francois, 1995; Slifka et al., 2000; Assarsson et al., 2000), conceivable that NK/DC hybrid cells arise in our system
phenotypic features shared by NK cells and DCs may as a consequence of NK-DC interactions in vivo, poten-
result from an activation-induced reconfiguration of cell tially following DC killing by NK cells. Recent reports
surface profiles. A basis for this promiscuous marker have demonstrated the direct targeting of DCs by NK
expression may be found in the lineage relationship of cells (Wilson et al., 1999) as well as DC-induced in-
DC and NK cells. While common progenitor cells for DC, creases of NK killing and IFN production (Fernandez
NK, T, and B cells have been described in humans (Galy et al., 1999). It has been speculated that such interac-
et al., 1995), more restricted bipotential NK and DC pre- tions may play a role in early immunity to infection,
cursors suggest that DC and NK cells branch off the immune homeostasis, and prevention of autoimmunity
T lineage through a common intermediate progenitor (Chambers and Ljunggren, 1999).
(Marquez et al., 1998). Similarly, lineage-restricted pro- In summary, DC-NK interactions, including DC killing
genitors for NK, DC, and follicular cells but not T or and subsequent antigen presentation by NK cells, might
B cells have been found in mice (Mebius et al., 1997). constitute a link between innate and adaptive immunity
Further evidence for a shared origin has come from of which the bitypic NK/DC cells described here could
studies using flt3L, a growth factor for hematopoietic represent a phenotypic and functional extension. The
progenitors that expands both DC (Maraskovsky et al., capacity of these cells to decisively influence developing
1996) and NK cells (Shaw et al., 1998) in vivo. Conversely, immune responses in the context of costimulatory
flt3L-deficient mice have a marked deficiency of both blockade is evidenced in our study by specific modula-
DC and NK cells but not NKT cells (McKenna et al., tion of diabetogenic T cell immunity and forestalling
2000). progression to the clinically overt stage of virus-induced
Phenotypic correspondence among DC and NK cells autoimmune disease. Further exploration of this para-
is complemented by functional commonalities. B7.1 ex- digm might extend this approach to other therapeutic
pression has been found on NK cell lines (Azuma et al., situations where induction of specific tolerance is de-
1993) and human CD56NK cells were shown to express sired.
MHC class II and function as APCs (D’Orazio and Stein-
Streilein, 1996). DCs freshly isolated from rat spleens Experimental Procedures
were cytotoxic for the NK-sensitive YAC-1 cell line (Trin-
Miceite et al., 2000) and cultured cytotoxic DCs expressed
Generation and characterization of transgenic RIP-GP and RIP-NPthe NK receptor NKR-P1 (Josien et al., 1997). Murine
H-2b (backcross F10–12 to C57BL/6 [B6]) has been described pre-CD8 DC induced T cell apoptosis in a FasL-dependent
viously (Oldstone et al., 1991; von Herrath et al., 1994). In some
manner (Suss and Shortman, 1996), while human myeloid- experiments, nontransgenic B6 mice were used. Mice were housed
related CD11c and monocyte-derived DCs acquired under specific pathogen-free conditions at The Scripps Research
tumoricidal activity after induction of TRAIL (TNF-related Institute (TSRI).
apoptosis-inducing ligand) with type I and II interferons
Blood Glucose Values(Fanger et al., 1999). Interestingly, induction of TRAIL,
Blood samples obtained from the retro-orbital plexus of anesthe-also recently shown to be a negative regulator of T cell
tized mice were evaluated using the ACCUCHECK III (von Herrathresponses (Song et al., 2000), was abrogated in the
et al., 1995).presence of CD40L-mediated costimulation (Vidalain et
al., 2001), suggesting the possibility for a release of DC
Antibody Treatments
cytotoxicity by CD40L blockade. However, other cyto- Antibodies for in vivo treatment were obtained from Roche Research
toxic pathways have to be considered since CD40L- Laboratories, Nutley, NJ (aB7.1 [1G10] and aB7.2 [2D10], Kuchroo
activated mature DC acquired partially TNF-dependent et al., 1995) and from BDPharMingen, La Jolla, CA (aCD40L [MR1]).
Rat isotype and hamster Ig control antibodies (BDPharMingen) werecytotoxicity (Vidalain et al., 2001). In the present study,
used as negative controls. Antibody stocks were diluted in phos-we have found splenic CD11c/DX5-bearing cells also
phate-buffered saline (PBS) to a final concentration of 1 mg/ml, andin unimmunized mice. While this population comprised
100 g/dose was administered i.v. into the tail vein.1/3 of splenic CD11c cells, it expanded to 2/3 5 days
after LCMV infection and demonstrated the capacity Viruses
for antigen processing/presentation and, in contrast to LCMV Armstrong clone 53b, plaque-purified three times on Vero
CD11c/DX5	 cells, direct ex vivo cytolytic activity. cells and stocks prepared by a single passage on BHK-21 cells,
Thus, NK/DC killing, potentially promoted in vivo by vi- was used throughout experiments. Six- to ten-week-old mice were
infected with a single dose of 1–2  105 plaque-forming units (pfu)rus-induced upregulation of type I interferons (Biron,
i.p. In some experiments, animals were infected with 107 pfu recom-2001), may function as a regulatory mechanism for de-
binant vaccinia virus sc11 or 2  105 pfu Pichinde virus, strainveloping immune responses.
AN3739 i.p.
Finally, the hybrid phenotype described in our study
may result from direct DC-NK interactions. Reports Peptides
about such interactions have been scarce (Chambers Peptides used for stimulation cultures were the dominant Db-
and Ljunggren, 1999), but evidence suggests that NK restricted LCMV epitopes GP33–41 and NP396–404 (Gairin et al., 1995)
(TSRI Peptide Core Facility or Peptidogenic, Livermore, CA) as wellcells can shape the outcome of adaptive immune re-
Immunity
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as IAb-restricted epitopes GP61-80 and NP309-328 (Oxenius et al., 1995) the CD11c-enriched fraction from the 12%/0% Optiprep interphase
(Ruedl et al., 1996). Equivalent results were achieved with adoptive(Chiron, Clayton Victoria, Australia).
transfers of CD11c cells enriched by either method. For isolation
of DX5 and DX5	 CD11c cells, spleen cell suspension wasCTL Assays
preenriched by depletion of B220, CD8, and CD4 cells usingEx vivo CTL activity was measured in a standard 5–6 hr in vitro 51Cr
magnetic beads (Dynal) under suboptimal conditions. Cells wererelease assay using syngeneic (MC57, H-2b) or allogeneic (Balb/Cl7,
subsequently stained for CD11c and DX5, and viable DX5 and DX5	H-2d) target cells infected with LCMV (MOI 
 1) or coated with
CD11c cells were sorted on a FACSVantage SE flow cytometerMHC I-restricted LCMV peptides (10	5 M) (von Herrath et al., 1995).
(Beckton Dickinson). Purity was 98%. Depleted, enriched, as wellSecondary CTL assays were performed following splenocyte restim-
as unmodified cell populations were subsequently transferred i.v.ulation for 5 days with irradiated, syngeneic LCMV-infected perito-
into LCMV-infected, prediabetic RIP-GP recipients or used in NKneal exsudate cells (PECs) under suboptimal conditions (no IL-2).
cell and APC assays.For precursor frequency analysis, spleen cells were serially diluted
and cultured in 96-well flat-bottom plates in the presence of T cell
NK Cell Assaysgrowth factor (primarily containing IL-2), irradiated LCMV-infected
Cytotoxic ex vivo NK cell activity was assayed in a 51Cr releasePECs, and spleen feeder cells. After 8–10 days, cultures were as-
assay on uninfected and LCMV-infected YAC and RMAS target cellssayed for CTL activity on LCMV-infected and uninfected target cells.
(a gift from M. Kronenberg) at E:T ratios of 300:1, 100:1, 50:1, andPrecursor frequencies were calculated as described (von Herrath
25:1. Positive controls were spleen cells derived from mice 3 andet al., 1995).
4 days after LCMV infection (Welsh et al., 1991).
Flow Cytometry
APC AssayFor surface stains, single-cell suspensions prepared from lymphatic
5 104 purified DX5	 and DX5CD11c cells were loaded overnightorgans were treated with FcBlock (BDPharMingen) to block Fc re-
at 37C with hen egg white ovalbumin (100 g/ml) (Worthingtonceptors prior to using the following fluorescein isothiocyanate-, phy-
Biochemical Corporation, Lakewood, NJ) in triplicate wells of a 96-coerythrin-, CyChrome-, peridinin chlorophyll-a protein-, or allophy-
well flat-bottom plate. Cells were subsequently washed and seriallycocyanin-conjugated, biotinylated, and/or purified antibodies
diluted (2-fold steps), and 5  104 B3Z cells were added per well;(BDPharMingen, unless noted otherwise): CD4 (RM4-5), CD8a (53-
B3Z is a KbOVA257–264-specific T cell hybridoma transfected with a6.7), CD11b (M1/70), CD11c (HL3), CD40L (MR1), CD44 (IM7),
NFAT-lacZ reporter construct (Karttunen et al., 1992). CoculturesCD45R/B220 (RA3-6B2), CD69 (H1.2F3), CD80/B7.1 (16-10A1),
were incubated at 37C overnight, and the assay was then devel-CD86/B7.2 (GL1), TCR  chain (H57-597), MHC II (AF6, KH74), NK1.1
oped with the chromogenic lacZ substrate chlorophenol red(PK136), pan-NK cells (DX5), F4/80 (Caltag, Burlingame, CA), IFN
-galactoside (Calbiochem, La Jolla, CA) and read at A595 as de-(XMG1.2), and TNF (MP6-XT22). For five- and six-color flow cytom-
scribed (Shastri and Gonzalez, 1993). Positive and negative controlsetry, CD8 (53-6.7) and CD4 (H129.19) Red 613 conjugates (Gibco),
employed the EL4 thymoma (ATCC, Manassas, VA) similarly loadedCD11b-PerCP-Cy5.5 as well as Streptavidin-PharRed, were used.
overnight with either 100 g/ml ovalbumin or 1 ng/ml OVA257 peptideIn some experiments, propidium iodide incorporation (5 g/ml; Ho-
(SIINFEKL).mann et al., 2001) was used to analytically exclude dead cells. For
intracellular stains, single-cell suspensions were restimulated for
Ribonuclease Protection Assays5–7 hr with 1 g/ml MHC class I- or 2 g/ml MHC class II-restricted
RPAs were performed as described using reagents and protocolsviral peptides in the presence of 10–50 U/ml recombinant human
provided by BDPharMingen (Christen et al., 2001).IL-2 (BDPharMingen) and 1 g/ml brefeldin A (Sigma, St. Louis, MO).
In some cases, polyclonal stimulation was provided by PMA (5 ng/
ml) and ionomycin (500 ng/ml) (Sigma). Staining of cell surface anti- Acknowledgments
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